Aushon Expands Portfolio of Ultrasensitive Cira™ Assays with Additional New Tests
Ultrasensitive Assay Kits Now Available for
Human Cytokines IL-1a, IL-4, and IL-12p70
Billerica, Mass. — December 15, 2015 —
Aushon BioSystems, a leading provider of products and services for multiplex quantitative detection of protein biomarkers, today announced that it has expanded its offering of Ultrasensitive Cira™ Assays to include kits for Human Cytokines IL-1a, IL-4, and IL-12p70. These new kits are in addition to the previously launched ultrasensitive kits for detection of IFNg, IL-1b, IL-6, IL-10, and TNFa.
“Our customers have been enthusiastic about the benefits of being able to detect low abundance and immune-suppressed proteins at femtogram/mL levels of detection without sacrificing the precision and throughput achieved on our Cira™ platform. With the ability to complete the processing of multiple plates in under three hours and the ability to read each 96-well plate in just few minutes, these kits are ideal for large clinical studies requiring quick turn around times” said Susan Vogt, CEO of Aushon.
Added Pete Honkanen, Aushon’s founder and COO, “The ability to measure previously undetectable proteins with a high degree of precision opens up new possibilities in research and diagnostic applications. With the Cira™ platform, researchers are able to combine the benefits of multiplexed assays and ultrasensitive detection levels on a single instrument.”
About Aushon BioSystems
Aushon BioSystems, Inc. provides a comprehensive suite of multiplex immunoassay products and services for protein biomarker discovery, development, and analysis to leading pharmaceutical, biotechnology, academic, and diagnostic clients worldwide. Our unique combination of proprietary microarray printing, extensive biomarker content, and innovative Cira™ immunoassay platform delivers exceptional performance, quality, and reliability to accelerate preclinical and clinical biomarker research. Our customers, who include leading pharmaceutical companies, contract research organizations and clinical reference laboratories, trust Aushon to supply the most reliable biomarker data available, accelerating the evaluation of potential drug candidates and advancing the use of biomarker profiles in diagnostics.